UPB Stock Analysis: Buy, Sell, or Hold?
UPB - Upstream Bio, Inc. Common Stock
$6.10
-0.28 (-4.39%)
▼
5d:
-13.48%
30d:
-34.83%
90d:
-33.91%
WAIT
LOW Confidence
Analysis Updated: Jun 12, 2026 12:00 AM ET
Earnings: Aug 05, 2026
Get Alerted When UPB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: UPB is down 13.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: UPB is down 13.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: UPB is currently trading at $6.10, which is considered oversold relative to its 30-day fair value range of $7.12 to $9.10.
Technical Outlook: Technically, UPB is in a strong downtrend. Immediate support is located at $5.85, while resistance sits at $8.64. Short-term momentum is weak, with the stock down 4.4% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $41.62 (+582.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, UPB is in a strong downtrend. Immediate support is located at $5.85, while resistance sits at $8.64. Short-term momentum is weak, with the stock down 4.4% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $41.62 (+582.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$7.12 -
$9.10
Company Quality Score
43/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.4%)
- BULLISH: Trading 582.4% below Wall St target ($41.62)
- WARNING: Recommendation downgraded due to -13.5% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$7.12 -
$9.10
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$5.85
Resistance Level
$8.64
Current Trend
Strong Downtrend
Technical data as of
Jun 12, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.01
Wall Street Target
$41.63
(+582.4%)
Revenue Growth (YoY)
82.7%
Share & Embed Analysis
Last updated: June 15, 2026 5:08 AM ET
Data refreshes hourly during market hours. Next update: 6:08 AM
Data refreshes hourly during market hours. Next update: 6:08 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is UPB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Michael Gray
SELL
852 shares
2026-03-16
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 63 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$102 | 58 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$31 | 58 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$22 | 61 BUY |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 59 HOLD |
